Mizuho Securities USA LLC Acquires 51,162 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Mizuho Securities USA LLC raised its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 625.5% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 59,341 shares of the biopharmaceutical company’s stock after purchasing an additional 51,162 shares during the period. Mizuho Securities USA LLC owned approximately 0.05% of Regeneron Pharmaceuticals worth $62,382,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Sachetta LLC raised its position in Regeneron Pharmaceuticals by 71.4% in the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 10 shares during the last quarter. Rakuten Securities Inc. grew its stake in shares of Regeneron Pharmaceuticals by 380.0% in the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 19 shares during the period. Stephens Consulting LLC purchased a new stake in Regeneron Pharmaceuticals in the second quarter worth approximately $26,000. Crewe Advisors LLC bought a new stake in Regeneron Pharmaceuticals in the 1st quarter worth approximately $28,000. Finally, Lynx Investment Advisory bought a new stake in Regeneron Pharmaceuticals during the second quarter valued at approximately $33,000. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Down 3.3 %

Shares of REGN opened at $756.81 on Friday. The company’s 50-day moving average price is $985.21 and its 200 day moving average price is $1,032.97. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 12-month low of $753.69 and a 12-month high of $1,211.20. The firm has a market cap of $83.17 billion, a P/E ratio of 18.73, a price-to-earnings-growth ratio of 3.04 and a beta of 0.15.

Analyst Ratings Changes

A number of brokerages have issued reports on REGN. Wolfe Research assumed coverage on Regeneron Pharmaceuticals in a research note on Friday. They issued an “outperform” rating and a $1,150.00 price target for the company. Citigroup started coverage on Regeneron Pharmaceuticals in a research note on Thursday. They set a “neutral” rating and a $895.00 target price on the stock. Leerink Partnrs cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. Wells Fargo & Company cut their price objective on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating for the company in a report on Tuesday, October 22nd. Finally, Piper Sandler lowered their target price on shares of Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. One analyst has rated the stock with a sell rating, four have assigned a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $1,099.55.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the transaction, the chief financial officer now directly owns 15,305 shares in the company, valued at approximately $18,447,575.65. This trade represents a 27.07 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 7.48% of the stock is owned by company insiders.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.